Efficacy and safety of second-line chemotherapy for patients with advanced non-small cell lung cancer complicated by interstitial lung disease.
Kenji OtsukaHiroshi NokiharaAtsushi MitsuhashiRyohiko OzakiYohei YabukiHiroto YonedaHirokazu OginoYasuhiko NishiokaPublished in: Thoracic cancer (2022)
Second-line chemotherapy among patients with NSCLC complicated by ILD showed a certain effectiveness, but some patients experienced the AE of ILD, which may lead to death. The risk of the AE of ILD must be considered especially for patients with UIP and low percentage VC.
Keyphrases
- interstitial lung disease
- systemic sclerosis
- advanced non small cell lung cancer
- rheumatoid arthritis
- idiopathic pulmonary fibrosis
- end stage renal disease
- epidermal growth factor receptor
- ejection fraction
- newly diagnosed
- small cell lung cancer
- locally advanced
- systematic review
- peritoneal dialysis
- prognostic factors
- squamous cell carcinoma
- patient reported outcomes